Eledon Pharmaceuticals, Inc. — Q2 2021 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2021. Eledon is a clinical-stage biopharmaceutical company developing targeted therapies; it has no approved products and has not generated product revenue. Its lead candidate, AT-1501, is an anti-CD40L antibody being developed for transplant rejection, autoimmune nephritis, and ALS.
Financial performance and position
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $4.2 million | $0.8 million | $9.9 million | $2.5 million |
| General and administrative expense | $3.7 million | $1.3 million | $7.1 million | $3.0 million |
| Net loss | $7.4 million | $2.6 million | $15.9 million | $10.8 million |
| Net loss per share | $0.50 | $2.74 | $1.07 | $11.31 |
| Cash used in operating activities | Not reported quarterly | Not reported quarterly | $12.6 million | $5.2 million |
At June 30, 2021, cash and cash equivalents were $101.1 million, working capital was $99.9 million, total assets were $184.3 million, total liabilities were $5.8 million, and accumulated deficit was $96.3 million. The company reported no outstanding debt or committed credit facilities. Operating margins are not meaningful for this pre-revenue company. Management said cash resources were sufficient to meet anticipated needs for at least 12 months from the financial statements’ issuance date.
Changes versus the comparable period
- First-half operating expenses rose to $17.0 million from $6.0 million, driven mainly by AT-1501 clinical and manufacturing activity, consulting, personnel, and higher stock-based compensation.
- First-half net loss increased by $5.1 million year over year despite the absence of the $4.8 million warrant-inducement expense recorded in 2020; a $1.1 million income-tax benefit in 2021 partly offset the loss.
- Cash declined by $13.1 million during the first half of 2021, versus a $27,000 decline in the first half of 2020. Financing cash flow was negative $0.45 million in 2021, compared with $5.2 million of warrant-exercise proceeds in 2020.
- Comparability is affected by the September 2020 Anelixis acquisition and the shift from the legacy ENT program to AT-1501 development. The 2020 quarter also included $0.49 million of restructuring expense; none was recorded in 2021.
Outlook, risks, and notable items
- Management expects continued losses and increased spending as AT-1501 development advances; further financing will be needed to fund operations and development. The company may seek equity or debt financing, collaborations, licensing, or other arrangements, with possible dilution or restrictions on operations.
- The company initiated a Phase 2a open-label ALS study in October 2020, planned for approximately 54 participants. Health Canada cleared a Phase 2 islet-transplant study in November 2020; COVID-19 contributed to delays in certain studies, including the Canadian islet study. The filing provides no specific financial guidance or dated trial-completion forecast.
- Management described the completed single-ascending-dose Phase 1 AT-1501 study as generally well tolerated, with a safety profile comparable to placebo. These early findings do not establish efficacy or predict later-stage outcomes.
- Key risks include clinical, regulatory, enrollment, manufacturing and funding uncertainty; reliance on third-party manufacturers and CROs; competition; intellectual-property exposure; and potential COVID-19 disruption. The company reported no material legal proceedings and no contingent liabilities requiring accrual at June 30, 2021.
- The ALSTDI license includes up to $6.0 million in remaining milestones for a first licensed product, possible additional milestones for a second product, and a $100,000 annual maintenance fee beginning at the earlier of January 1, 2022, first sublicense, or change in control. Sales royalties and additional sales-based milestone payments may also apply.
- A March 2021 equity distribution agreement permits up to $75.0 million of common-stock sales; no shares had been sold under it through June 30, 2021. Management reported effective disclosure controls and no material quarterly change in internal control over financial reporting.
Investor verification priorities
- Track cash consumption against management’s stated minimum 12-month cash outlook and assess the timing and terms of any additional financing.
- Verify AT-1501 trial enrollment, timelines, safety findings, and whether COVID-19 or manufacturing constraints cause further delays.
- Reconcile expense growth, especially clinical-materials and trial costs, personnel, and stock-based compensation, with development progress.
- Review potential dilution from equity issuance, outstanding warrants and preferred stock, and the unused equity distribution facility; 14,306,614 common shares were outstanding as of August 9, 2021.
- Assess the conditions and potential future costs under the ALSTDI license and the company’s dependence on third-party manufacturing and research providers.